Japanese Journal of Infectious Diseases
Online ISSN : 1884-2836
Print ISSN : 1344-6304
ISSN-L : 1344-6304
Safety of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine in adults in Japan
Mugen UjiieShinya TsuzukiMichiyo SuzukiMasayuki OtaTetsuya SuzukiHidetoshi NomotoKei YamamotoSho SaitoAkatsuki KokazeNoriko Kinoshita
ジャーナル フリー 早期公開

論文ID: JJID.2020.947


Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is generally used for booster vaccination in Europe and the United States to avoid increased reactogenicity after diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccination in infants. However, Japan has extended the use of additional DTaP vaccination without reducing the antigen dose for diphtheria and pertussis to adolescents and adults despite limited reports on its safety in adults. This prospective observational questionnaire-based study investigated the occurrence of adverse events (AEs) following DTaP vaccination between June 2018 and June 2019 in participants aged 10 years or older. Of 250 eligible participants, 235 (94%) responded regarding AEs. Of these 235 participants, 133 (56.6%) reported AEs, with 39 reporting systemic AEs (16.6%) and 120 reporting local AEs (51.1%) attributed to DTaP vaccination. The incidence of local AEs was much higher with DTaP than with non-DTaP vaccinations (51.1% vs. 10.2%), and the AEs appeared later (p<0.01) and lasted longer (p<0.01) with DTaP vaccination. However, more than 75% of these AEs resolved within 7 days. DTaP vaccination was not associated with any serious AEs. These results indicate that the DTaP vaccine can be widely used as a booster in adults as an alternative to the Tdap vaccine.

© 2021 Authors
前の記事 次の記事